Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 17;64(1):e21.
doi: 10.1192/j.eurpsy.2021.13.

EPA guidance on treatment of negative symptoms in schizophrenia

Affiliations

EPA guidance on treatment of negative symptoms in schizophrenia

S Galderisi et al. Eur Psychiatry. .

Abstract

Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in the conceptualization and assessment is not yet fully reflected by treatment research. Nevertheless, there is a growing evidence base regarding the effects of biological and psychosocial interventions on negative symptoms. The importance of the distinction between primary and secondary negative symptoms for treatment selection might seem evident, but the currently available evidence remains limited. Good clinical practice is recommended for the treatment of secondary negative symptoms. Antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and due to positive symptoms. For most available interventions, further evidence is needed to formulate sound recommendations for primary, persistent, or predominant negative symptoms.However, based on currently available evidence recommendations for the treatment of undifferentiated negative symptoms (including both primary and secondary negative symptoms) are provided. Although it has proven difficult to formulate an evidence-based recommendation for the choice of an antipsychotic, a switch to a second-generation antipsychotic should be considered for patients who are treated with a first-generation antipsychotic. Antidepressant add-on to antipsychotic treatment is an option. Social skills training is recommended as well as cognitive remediation for patients who also show cognitive impairment. Exercise interventions also have shown promise. Finally, access to treatment and to psychosocial rehabilitation should be ensured for patients with negative symptoms. Overall, there is definitive progress in the field, but further research is clearly needed to develop specific treatments for negative symptoms.

Keywords: Negative symptoms; schizophrenia; treatment.

PubMed Disclaimer

Conflict of interest statement

S. Galderisi has been a consultant and/or advisor to or has received honoraria or grants from Millennium Pharmaceuticals, Innova Pharma-Recordati Group, Janssen Pharmaceutica NV, Sunovion Pharmarmaceuticals, Janssen-Cilag Polska Sp. zo. o., Gedeon Richter-Recordati, Pierre Fabre, Otsuka, and Angelini.

A. Mucci received honoraria, advisory board, or consulting fees from the following companies: Amgen Dompé, Angelini-Acraf, Astra Zeneca, Bristol-Myers Squibb, Gedeon Richter Bulgaria, Innova-Pharma, Janssen Pharmaceuticals, Lundbeck, Otsuka, Pfizer, and Pierre Fabre.

S. Dollfus received honoraria as expert/consultant by Fabre, Gedeon, Roche, and Takeda; invited Conferences: Lundbeck, Otsuka, Janssen, and has contracts with Prophase MedAvances and NeuroCogTrials.

S. Kaiser has royalties for cognitive training software from Schuhfried and advisory board honoraria from Recordati and Lundbeck on an institutional account for education and research.

I. Bitter has received in the past 5 years honoraria or consultation fees from Angelini, Eli Lilly, Gedeon Richter, Janssen/Janssen Cilag, and Sun Pharma.

All other authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Preferred reporting items for systematic reviews and meta-analyses flowchart of studies retrieved in the systematic literature search. *11,905 duplicates; 1,826 studies other than meta-analysis, randomized controlled trial, review, cohort study, open study, descriptive study, expert opinion; 843 studies published in journal not indexed in Embase or Medline; 2,895 studies on pathophysiological mechanisms of negative symptoms; 5,813 articles not related to any topic; 1,792 articles related to the assessment of negative symptoms; 158 studies conducted in animals. **Outdated; concerns about quality of meta-analytic procedures or of the original studies; addressed population/intervention/outcome not usable for formulation of recommendations.

References

    1. Bleuler E. Dementia praecox or the group of schizophrenias. New York, NY: International Universities Press; 1950.
    1. Jackson JH. Selected writings of JH Jackson. London, UK: Hodder and Stoughton; 1931.
    1. Kraepelin E. Dementia praecox and paraphrenia. Chicago, IL: Chicago Medical Book Company; 1919.
    1. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677. - PubMed
    1. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14–24. - PMC - PubMed

MeSH terms